Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels (GLP-1 and GIP), which enhance insulin secretion and decrease glucagon secretion in a glucose-dependent manner. Unlike other DPP-4 inhibitors, it is primarily excreted via the biliary/gastrointestinal route rather than the kidneys.
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
* **Safety/Efficacy:** Not established for use in pediatric patients under 18 years of age.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary for patients with renal impairment (mild, moderate, or severe).
* **Hepatic Impairment:** No dosage adjustment necessary.
## Contraindications
* Known hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, urticaria).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or sulfonylureas).
* **Serious:** Acute pancreatitis (discontinue if suspected), bullous pemphigoid, severe arthralgia (post-marketing reports), and hypersensitivity reactions.
## Key Drug Interactions
* **P-glycoprotein/CYP3A4 Inducers:** Strong inducers (e.g., rifampin) may decrease linagliptin plasma concentrations. Avoid concomitant use; if unavoidable, monitor glycemic control closely.
* **Insulin/Sulfonylureas:** Concomitant use increases the risk of hypoglycemia. Consider a dose reduction of the insulin secretagogue or insulin.
## Monitoring
* **Glycemic Control:** HbA1c (typically every 3–6 months); self-monitoring of blood glucose.
* **Safety:** Monitor for symptoms of pancreatitis (persistent severe abdominal pain) and bullous pemphigoid (blistering or skin erosions).
## Clinical Pearls
* Linagliptin is unique among DPP-4 inhibitors because it does not require renal dose adjustments, making it a convenient choice for patients with chronic kidney disease.
* It does not cause weight gain and has a low risk of hypoglycemia when used as monotherapy.
* May be taken with or without food.
* If a dose is missed, take it as soon as remembered, but do not take two doses on the same day.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify drug dosages, contraindications, and potential drug interactions with the most current manufacturer prescribing information, institutional protocols, or clinical decision support tools before prescribing or administering medication.
